VETmAb Biosciences
About VETmAb Biosciences
VETmAb BIO develops monoclonal antibodies specifically designed for treating debilitating diseases in dogs and cats, utilizing human-validated targets to reduce technical risk in veterinary medicine. The company addresses the lack of effective biopharmaceutical treatments in the veterinary field by leveraging proprietary technologies to create targeted therapies for unmet medical needs in pets.
<problem> The veterinary field lacks effective biopharmaceutical treatments for debilitating diseases in dogs and cats, resulting in unmet medical needs for pets. Existing treatments often have limited efficacy or significant side effects, leaving veterinarians with few options for managing complex conditions. </problem> <solution> VETmAb BIO develops species-specific monoclonal antibodies designed to treat debilitating diseases in companion animals. By focusing on human-validated therapeutic targets, VETmAb BIO aims to reduce technical risk and accelerate the development of novel veterinary biologics. The company's approach involves creating targeted therapies that address the underlying causes of disease, offering improved efficacy and safety profiles compared to traditional treatments. These therapies are intended to provide veterinarians with innovative tools to enhance the quality of life for dogs and cats suffering from chronic or life-threatening conditions. </solution> <features> - Species-specific monoclonal antibody development for dogs and cats - Focus on human-validated therapeutic targets to mitigate technical risk - Targeted therapies designed to address the underlying causes of disease </features> <target_audience> The primary customers are veterinarians specializing in companion animal care, as well as veterinary hospitals and specialty clinics seeking advanced treatment options. </target_audience>
What does VETmAb Biosciences do?
VETmAb BIO develops monoclonal antibodies specifically designed for treating debilitating diseases in dogs and cats, utilizing human-validated targets to reduce technical risk in veterinary medicine. The company addresses the lack of effective biopharmaceutical treatments in the veterinary field by leveraging proprietary technologies to create targeted therapies for unmet medical needs in pets.
Where is VETmAb Biosciences located?
VETmAb Biosciences is based in San Diego, United States.
When was VETmAb Biosciences founded?
VETmAb Biosciences was founded in 2022.
How much funding has VETmAb Biosciences raised?
VETmAb Biosciences has raised 2580000.
Who founded VETmAb Biosciences?
VETmAb Biosciences was founded by Denise Bevers.
- Denise Bevers - Founder/CEO
- Location
- San Diego, United States
- Founded
- 2022
- Funding
- 2580000
- Employees
- 4 employees